These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 31586071)

  • 1. Transcriptomic profiling of the myeloma bone-lining niche reveals BMP signalling inhibition to improve bone disease.
    Gooding S; Olechnowicz SWZ; Morris EV; Armitage AE; Arezes J; Frost J; Repapi E; Edwards JR; Ashley N; Waugh C; Gray N; Martinez-Hackert E; Lim PJ; Pasricha SR; Knowles H; Mead AJ; Ramasamy K; Drakesmith H; Edwards CM
    Nat Commun; 2019 Oct; 10(1):4533. PubMed ID: 31586071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sostdc1: A soluble BMP and Wnt antagonist that is induced by the interaction between myeloma cells and osteoblast lineage cells.
    Faraahi Z; Baud'huin M; Croucher PI; Eaton C; Lawson MA
    Bone; 2019 May; 122():82-92. PubMed ID: 30776499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activin A receptor type 1-mediated BMP signaling regulates RANKL-induced osteoclastogenesis via canonical SMAD-signaling pathway.
    Omi M; Kaartinen V; Mishina Y
    J Biol Chem; 2019 Nov; 294(47):17818-17836. PubMed ID: 31619522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the BMP Pathway in Prostate Cancer Induced Bone Disease.
    Straign DM; Ihle CL; Provera MD; Owens P
    Front Endocrinol (Lausanne); 2021; 12():769316. PubMed ID: 34956082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BMP Ligand Trap ALK3-Fc Attenuates Osteogenesis and Heterotopic Ossification in Blast-Related Lower Extremity Trauma.
    Strong AL; Spreadborough PJ; Dey D; Yang P; Li S; Lee A; Haskins RM; Grimm PD; Kumar R; Bradley MJ; Yu PB; Levi B; Davis TA
    Stem Cells Dev; 2021 Jan; 30(2):91-105. PubMed ID: 33256557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma.
    Gan ZY; Fitter S; Vandyke K; To LB; Zannettino AC; Martin SK
    Eur J Haematol; 2015 Apr; 94(4):343-54. PubMed ID: 25179233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined treatment with a transforming growth factor beta inhibitor (1D11) and bortezomib improves bone architecture in a mouse model of myeloma-induced bone disease.
    Nyman JS; Merkel AR; Uppuganti S; Nayak B; Rowland B; Makowski AJ; Oyajobi BO; Sterling JA
    Bone; 2016 Oct; 91():81-91. PubMed ID: 27423464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma.
    McDonald MM; Reagan MR; Youlten SE; Mohanty ST; Seckinger A; Terry RL; Pettitt JA; Simic MK; Cheng TL; Morse A; Le LMT; Abi-Hanna D; Kramer I; Falank C; Fairfield H; Ghobrial IM; Baldock PA; Little DG; Kneissel M; Vanderkerken K; Bassett JHD; Williams GR; Oyajobi BO; Hose D; Phan TG; Croucher PI
    Blood; 2017 Jun; 129(26):3452-3464. PubMed ID: 28515094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-host cell interactions in the bone disease of myeloma.
    Fowler JA; Edwards CM; Croucher PI
    Bone; 2011 Jan; 48(1):121-8. PubMed ID: 20615487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel bone morphogenetic protein receptor inhibitor JL5 suppresses tumor cell survival signaling and induces regression of human lung cancer.
    Newman JH; Augeri DJ; NeMoyer R; Malhotra J; Langenfeld E; Chesson CB; Dobias NS; Lee MJ; Tarabichi S; Jhawar SR; Bommareddy PK; Marshall S; Sadimin ET; Kerrigan JE; Goedken M; Minerowicz C; Jabbour SK; Li S; Carayannopolous MO; Zloza A; Langenfeld J
    Oncogene; 2018 Jul; 37(27):3672-3685. PubMed ID: 29622797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Applications of small molecule BMP inhibitors in physiology and disease.
    Hong CC; Yu PB
    Cytokine Growth Factor Rev; 2009; 20(5-6):409-18. PubMed ID: 19914855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease.
    Garcia-Gomez A; Li T; de la Calle-Fabregat C; Rodríguez-Ubreva J; Ciudad L; Català-Moll F; Godoy-Tena G; Martín-Sánchez M; San-Segundo L; Muntión S; Morales X; Ortiz-de-Solórzano C; Oyarzabal J; San José-Enériz E; Esteller M; Agirre X; Prosper F; Garayoa M; Ballestar E
    Nat Commun; 2021 Jan; 12(1):421. PubMed ID: 33462210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivo.
    Lath DL; Buckle CH; Evans HR; Fisher M; Down JM; Lawson MA; Chantry AD
    PLoS One; 2018; 13(6):e0199517. PubMed ID: 29924867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined inhibition of the BMP pathway and the RANK-RANKL axis in a mixed lytic/blastic prostate cancer lesion.
    Virk MS; Alaee F; Petrigliano FA; Sugiyama O; Chatziioannou AF; Stout D; Dougall WC; Lieberman JR
    Bone; 2011 Mar; 48(3):578-87. PubMed ID: 21073986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wnt and BMP signaling pathways co-operatively induce the differentiation of multiple myeloma mesenchymal stem cells into osteoblasts by upregulating EMX2.
    Wei XF; Chen QL; Fu Y; Zhang QK
    J Cell Biochem; 2019 Apr; 120(4):6515-6527. PubMed ID: 30450775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of bone morphogenetic protein signaling reduces vascular calcification and atherosclerosis.
    Derwall M; Malhotra R; Lai CS; Beppu Y; Aikawa E; Seehra JS; Zapol WM; Bloch KD; Yu PB
    Arterioscler Thromb Vasc Biol; 2012 Mar; 32(3):613-22. PubMed ID: 22223731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma.
    Standal T; Abildgaard N; Fagerli UM; Stordal B; Hjertner O; Borset M; Sundan A
    Blood; 2007 Apr; 109(7):3024-30. PubMed ID: 17138824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma.
    Tai YT; Chang BY; Kong SY; Fulciniti M; Yang G; Calle Y; Hu Y; Lin J; Zhao JJ; Cagnetta A; Cea M; Sellitto MA; Zhong MY; Wang Q; Acharya C; Carrasco DR; Buggy JJ; Elias L; Treon SP; Matsui W; Richardson P; Munshi NC; Anderson KC
    Blood; 2012 Aug; 120(9):1877-87. PubMed ID: 22689860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway.
    Kamiya N; Ye L; Kobayashi T; Mochida Y; Yamauchi M; Kronenberg HM; Feng JQ; Mishina Y
    Development; 2008 Nov; 135(22):3801-11. PubMed ID: 18927151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of bone morphogenetic proteins in myeloma cell survival.
    Holien T; Sundan A
    Cytokine Growth Factor Rev; 2014 Jun; 25(3):343-50. PubMed ID: 24853340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.